首页> 外文期刊>Antiviral Research >Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies.
【24h】

Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies.

机译:单克隆抗体可有效抑制耐药HIV蛋白酶变体。

获取原文
获取原文并翻译 | 示例
       

摘要

The monoclonal antibodies 1696 and F11.2.32 strongly inhibit the activity of wild-type HIV-1 protease (PR) by binding to epitopes at the enzyme N-terminus (residues 1-6) and flap residues 36-46, respectively. Here we demonstrate that these antibodies are also potent inhibitors of PR variants resistant to active-site inhibitors used as anti-AIDS drugs. Our in vitro experiments revealed that the inhibitory potency of single-chain fragments (scFv) of these antibodies is not significantly affected by the presence of mutations in PR; inhibition constants for drug-resistant protease variants are 5-11nM and 13-169nM for scFv1696 and for scFvF11.2.32, respectively. Tethered dimer of HIV-1 PR variant proved to be a model protease variant resistant to dissociative inhibition by 1696, and, strikingly, it also displayed resistance to inhibition by F11.2.32 suggesting that dimer dissociation also plays a role in the inhibitory action of F11.2.32.
机译:单克隆抗体1696和F11.2.32通过分别与酶N端(残基1-6)和襟翼残基36-46的表位结合,强烈抑制野生型HIV-1蛋白酶(PR)的活性。在这里,我们证明了这些抗体也是PR变体的有效抑制剂,可抵抗用作抗艾滋病药物的活性位点抑制剂。我们的体外实验表明,这些抗体的单链片段(scFv)的抑制能力不受PR中突变的影响。耐药蛋白酶变体的抑制常数对scFv1696和scFvF11.2.32分别为5-11nM和13-169nM。 HIV-1 PR变体的束缚二聚体被证明是一种模型蛋白酶变体,在1696年之前对解离抑制具有抗性,而且令人惊讶的是,它还显示出对F11.2.32抑制的抗性,表明二聚体解离在F11的抑制作用中也起作用.2.32。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号